112 related articles for article (PubMed ID: 24866849)
1. The novel capripoxvirus vector lumpy skin disease virus efficiently boosts modified vaccinia Ankara human immunodeficiency virus responses in rhesus macaques.
Burgers WA; Ginbot Z; Shen YJ; Chege GK; Soares AP; Müller TL; Bunjun R; Kiravu A; Munyanduki H; Douglass N; Williamson AL
J Gen Virol; 2014 Oct; 95(Pt 10):2267-2272. PubMed ID: 24866849
[TBL] [Abstract][Full Text] [Related]
2. A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV).
Shen YJ; Shephard E; Douglass N; Johnston N; Adams C; Williamson C; Williamson AL
Virol J; 2011 May; 8():265. PubMed ID: 21624130
[TBL] [Abstract][Full Text] [Related]
3. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
4. Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.
Nilsson C; Godoy-Ramirez K; Hejdeman B; Bråve A; Gudmundsdotter L; Hallengärd D; Currier JR; Wieczorek L; Hasselrot K; Earl PL; Polonis VR; Marovich MA; Robb ML; Sandström E; Wahren B; Biberfeld G
AIDS Res Hum Retroviruses; 2014 Mar; 30(3):299-311. PubMed ID: 24090081
[TBL] [Abstract][Full Text] [Related]
5. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.
Rosario M; Hopkins R; Fulkerson J; Borthwick N; Quigley MF; Joseph J; Douek DC; Greenaway HY; Venturi V; Gostick E; Price DA; Both GW; Sadoff JC; Hanke T
J Virol; 2010 Jun; 84(12):5898-908. PubMed ID: 20375158
[TBL] [Abstract][Full Text] [Related]
6. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.
Ramsburg E; Rose NF; Marx PA; Mefford M; Nixon DF; Moretto WJ; Montefiori D; Earl P; Moss B; Rose JK
J Virol; 2004 Apr; 78(8):3930-40. PubMed ID: 15047809
[TBL] [Abstract][Full Text] [Related]
7. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
8. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.
Casimiro DR; Chen L; Fu TM; Evans RK; Caulfield MJ; Davies ME; Tang A; Chen M; Huang L; Harris V; Freed DC; Wilson KA; Dubey S; Zhu DM; Nawrocki D; Mach H; Troutman R; Isopi L; Williams D; Hurni W; Xu Z; Smith JG; Wang S; Liu X; Guan L; Long R; Trigona W; Heidecker GJ; Perry HC; Persaud N; Toner TJ; Su Q; Liang X; Youil R; Chastain M; Bett AJ; Volkin DB; Emini EA; Shiver JW
J Virol; 2003 Jun; 77(11):6305-13. PubMed ID: 12743287
[TBL] [Abstract][Full Text] [Related]
9. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
10. Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination.
Rallón N; Mothe B; Lopez Bernaldo de Quiros JC; Plana M; Ligos JM; Montoya M; Muñoz-Fernández MA; Esteban M; Garcia F; Brander C; Benito JM;
AIDS; 2016 Feb; 30(4):553-62. PubMed ID: 26558724
[TBL] [Abstract][Full Text] [Related]
11. Development of a DNA-MVA/HIVA vaccine for Kenya.
Hanke T; McMichael AJ; Mwau M; Wee EG; Ceberej I; Patel S; Sutton J; Tomlinson M; Samuel RV
Vaccine; 2002 May; 20(15):1995-8. PubMed ID: 11983261
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
13. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
Goepfert PA; Elizaga ML; Seaton K; Tomaras GD; Montefiori DC; Sato A; Hural J; DeRosa SC; Kalams SA; McElrath MJ; Keefer MC; Baden LR; Lama JR; Sanchez J; Mulligan MJ; Buchbinder SP; Hammer SM; Koblin BA; Pensiero M; Butler C; Moss B; Robinson HL; ;
J Infect Dis; 2014 Jul; 210(1):99-110. PubMed ID: 24403557
[TBL] [Abstract][Full Text] [Related]
14. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
Rosario M; Fulkerson J; Soneji S; Parker J; Im EJ; Borthwick N; Bridgeman A; Bourne C; Joseph J; Sadoff JC; Hanke T
J Virol; 2010 Aug; 84(15):7815-21. PubMed ID: 20484495
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.
Keefer MC; Frey SE; Elizaga M; Metch B; De Rosa SC; Barroso PF; Tomaras G; Cardinali M; Goepfert P; Kalichman A; Philippon V; McElrath MJ; Jin X; Ferrari G; Defawe OD; Mazzara GP; Montefiori D; Pensiero M; Panicali DL; Corey L;
Vaccine; 2011 Feb; 29(10):1948-58. PubMed ID: 21216311
[TBL] [Abstract][Full Text] [Related]
17. Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.
Khattar SK; Manoharan V; Bhattarai B; LaBranche CC; Montefiori DC; Samal SK
mBio; 2015 Jul; 6(4):e01005. PubMed ID: 26199332
[TBL] [Abstract][Full Text] [Related]
18. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.
Mooij P; Balla-Jhagjhoorsingh SS; Koopman G; Beenhakker N; van Haaften P; Baak I; Nieuwenhuis IG; Kondova I; Wagner R; Wolf H; Gómez CE; Nájera JL; Jiménez V; Esteban M; Heeney JL
J Virol; 2008 Mar; 82(6):2975-88. PubMed ID: 18184713
[TBL] [Abstract][Full Text] [Related]
19. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.
Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y
AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
